Type 2 Diabetes
Top in endocrinology: Hypogonadism drug, SGLT2 inhibitors
The FDA will review an oral testosterone undecanoate softgel manufactured by Marius Pharmaceuticals as a potential treatment for hypogonadism in men. The announcement was the top story in endocrinology last week.
USPSTF proposes ‘major change’ to prediabetes, diabetes screening recommendations
The U.S. Preventive Services Task Force released a draft recommendation that, if adopted, would lower the age to start screening adults with overweight or obesity for prediabetes and type 2 diabetes from 40 to 35 years.
CV benefits of type 2 diabetes agents may extend to type 1, but more data needed
Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population.
SGLT2 inhibitors not cost-effective for glycemic management alone in type 2 diabetes
SGLT2 inhibitors provide limited glycemic management benefits and may not be cost-effective for most people with type 2 diabetes, according to a study published in the Journal of Diabetes and Its Complications.
Regular physical activity reduces risk for type 2 diabetes, independent of pollution
Adults who routinely engage in a high level of physical activity may be able to reduce their risk for developing type 2 diabetes, even in areas with high air pollution, according to a study published in Diabetologia.
Patients with ‘severely’ high albuminuria reap most kidney benefits from canagliflozin
Adding to existing evidence that shows the benefits of canagliflozin for patients with type 2 diabetes, researchers found those with “severely increased” baseline albuminuria experienced the most protective kidney effects.
Obesity drives higher CV, renal risks for adolescents with type 1 diabetes
Cardiovascular and metabolic derangements observed among adolescents with type 1 diabetes and obesity parallel those of youths with type 2 diabetes, suggesting a critical need for lifestyle management, data show.
AHA, ADA award community grants to improve CVD risk in type 2 diabetes
The American Heart Association, in collaboration with the American Diabetes Association, accounted they awarded 10 community grants of up to $900,000 to help patients with type 2 diabetes lower their risk for CVD.
Prescribe SGLT2 inhibitors, GLP-1 receptor agonists ‘as early as possible’ for CV benefit
Adults with type 2 diabetes assigned an SGLT2 inhibitor or a GLP-1 receptor agonist during cardiovascular outcomes trials derived benefit from the therapies regardless of whether they were prescribed insulin, according to a meta-analysis.
Prediabetes diagnosis poor predictor of disease progression for older adults
Older adults with an HbA1c in the prediabetes range were far more likely to revert to normoglycemia or die during 5-year follow-up than to progress to overt type 2 diabetes, according to a community-based study.